Join the club for FREE to access the whole archive and other member benefits.

Juvena Therapeutics receives $50M to uncover therapeutic links between secreted proteins and diseases


Key points from article :

Co-led by Mubadala Capital and Horizons Ventures, funding will power Juvena’s AI-enabled drug discovery platform to map the therapeutic potential of secreted proteins.

Juvena Therapeutics announced that it has raised $41 million in Series A, bringing its total funding to $50 million.

It will advance the company’s biologics pipeline targeting chronic and age-related diseases.

Secreted proteins are a proven class of biologics with tremendous therapeutic potential.

They regulate tissue repair and regeneration, organ development, and immune response to disease.

To systematically uncover the therapeutic links between secreted proteins and diseases, Juvena has developed a computational platform.

It combines a compounding database mapping secreted proteins to specific diseases.

“We are thrilled to scale our platform ... and chronic, debilitating diseases,” said Hanadie Yousef, Co-founder and Chief Executive Officer of Juvena. 

Its a fully integrated approach for developing biologics for chronic and age-related diseases

Mentioned in this article:

Click on resource name for more details.

Hanadie Yousef

Co-founder and CEO of Juvena Therapeutics

Juvena Therapeutics

Biopharma discovering novel protein-based therapeutics that promote tissue regeneration